Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Receivables (2016 - 2025)

Protalix BioTherapeutics has reported Change in Receivables over the past 16 years, most recently at -$5.9 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$5.9 million for Q4 2025, down 881.65% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (up 354.21% YoY), and the annual figure for FY2025 was $5.9 million, up 354.21%.
  • Change in Receivables for Q4 2025 was -$5.9 million at Protalix BioTherapeutics, down from $4.8 million in the prior quarter.
  • Over the last five years, Change in Receivables for PLX hit a ceiling of $7.1 million in Q2 2024 and a floor of -$8.4 million in Q3 2024.
  • Median Change in Receivables over the past 5 years was $1.5 million (2024), compared with a mean of $311350.0.
  • Biggest five-year swings in Change in Receivables: soared 254.98% in 2023 and later plummeted 881.65% in 2025.
  • Protalix BioTherapeutics' Change in Receivables stood at -$3.0 million in 2021, then crashed by 47.81% to -$4.5 million in 2022, then increased by 16.41% to -$3.8 million in 2023, then soared by 120.0% to $752000.0 in 2024, then plummeted by 881.65% to -$5.9 million in 2025.
  • The last three reported values for Change in Receivables were -$5.9 million (Q4 2025), $4.8 million (Q3 2025), and $4.6 million (Q2 2025) per Business Quant data.